Science Current Events | Science News | Brightsurf.com
 

Brain tumors: New therapy surprisingly successful

March 06, 2009

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours. This has been demonstrated by researchers at Bonn University working in co-operation with German and Swiss colleagues in a current study. They treated 39 patients who had been diagnosed with a so-called gliablastoma. The patients survived on average 23 months; with the standard therapy the mean would have been 14.6 months. Glioblastomas are the most aggressive and the commonest brain tumours. Left untreated, they prove fatal within just a few weeks. The study has been published in the Journal of Clinical Oncology (doi: 10.1200/JCO.2008.19.2195).

Even today, glioblastomas are untreatable - something which even the new combination therapy cannot change. Nevertheless, Professor Dr. Ulrich Herrlinger of Bonn University's Schwerpunkt Klinische Neuroonkologie speaks of an outstanding success: "This unusually manifest extension of the survival time has surprised even us. Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimise this therapy. Planning for this is already in hand in Bonn".

Up to now, doctors have treated glioblastomas using radiotherapy with concomitant chemotherapy. The "gold standard" for this for the last few years has been the active agent temozolomide. This is still celebrated as the most important breakthrough in the treatment of glioblastomas. The researchers combined this preparation with the drug lomustine. At the same time, the patients were given radiotherapy. The 39 patients thus treated survived the tumour for an average of 23.1 months. With the standard therapy, this time is over one third shorter. Seven patients even survived for over four years.

Genes decide the Success of the Therapy

It would appear that certain changes in the genotype are critical for the success of this therapy. "With eleven participants in the study, the information of one gene had been subjected to a characteristic modification", Ulrich Herrlinger declares. "These patients survived on average a good 34 months. With the other patients, these drugs appeared to bring no apparent advantage vis-à-vis pure radiotherapy - at least, not in the dosage we tested. It is possible that a simple gene test could decide for whom a concomitant chemotherapy might be of benefit". One disadvantage of the new method are the side-effects. However, these mostly occur during the several months of the treatment phase. "After that they normally disappear completely, and the patients have no further complaints about them", Herrlinger stresses.

Working in co-operation with the Life&Brain-Zentrum in Bonn, the search is now on for more compatible, more effective, drugs. "Amongst other things, we now want to use cell cultures from original tumours to study precisely what the preparations we used in the study really effect", Dr. Martin Glas, one of the authors of the study, declares.

University of Bonn


Related Glioblastomas Current Events and Glioblastomas News Articles


Gene therapy against brain cancer
Only a few days ago, the press (especially in English-speaking countries) enthusiastically announced the publication of a study that described in great detail the genetics of breast cancer, a discovery that according to many marks a breakthrough in the battle against this cancer.

Innate immune landscape in glioblastoma patient tumors
Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might be effective in this devastating malignancy.

Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS
Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.

TGen identifies drug that could limit the spread of deadly brain tumors
In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.

Malignant network makes brain cancer resistant
Incurable astrocytomas, including the particularly malignant glioblastomas, diffusively grow like mycelium into healthy brain tissue.

A hint of increased brain tumor risk -- 5 years before diagnosis
A new study suggests that changes in immune function can occur as long as five years before the diagnosis of a brain tumor that typically produces symptoms only three months before it is detected.

Epigenetic driver of glioblastoma provides new therapeutic target
Cancer's ability to grow unchecked is often attributed to cancer stem cells, a small fraction of cancer cells that have the capacity to grow and multiply indefinitely. How cancer stem cells retain this property while the bulk of a tumor's cells do not remains largely unknown.

Detroit patients' contributions to national study re-define low-grade brain tumor diagnosis
Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified - and ultimately treated.

Scientists find way to disrupt brain tumor stem cells
Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return.

Study discovers new method of classifying low-grade brain tumors
A Case Comprehensive Cancer Center (CCCC) brain surgeon and neurosurgery professor is among the primary authors of a new approach to classifying tumors that could lead to significant improvements in their diagnosis and treatment.
More Glioblastomas Current Events and Glioblastomas News Articles

A Statistic of One: My Walk With Glioblastoma Multiforme

A Statistic of One: My Walk With Glioblastoma Multiforme
by Stephen Hatrak (Author)


A Statistic of One: My Walk with Glioblastoma Multiforme traces Stephen Hatrak's life from his diagnosis of glioblastoma multiforme, the deadliest of malignant brain tumors, to the present. He chronicles the trials and tribulations he faced and the losses he suffered along his journey. Faith and inner strength are formidable allies in overcoming any tragedy in one's life, and they played vital roles in his struggle. He was told from the start that the he might have twelve months to live; even so, he defi ed the odds and, six years later, is telling his own story. Despite the dire statistics associated with a diagnosis of glioblastoma, there are several stories of long-term survival; these stories gave him hope that this cancer could be tamed. To overcome this challenge in his life, he had...

Medifocus Guidebook on: Glioblastoma

Medifocus Guidebook on: Glioblastoma
by Medifocus com Inc (Author)


The MediFocus Guidebook on Glioblastoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Glioblastoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Glioblastoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations...

Glioblastoma Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Glioblastoma Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by Icon Health Publications (Author)


This is a 3-in-1 reference book. It gives a complete medical dictionary covering hundreds of terms and expressions relating to glioblastoma multiforme. It also gives extensive lists of bibliographic citations. Finally, it provides information to users on how to update their knowledge using various Internet resources. The book is designed for physicians, medical students preparing for Board examinations, medical researchers, and patients who want to become familiar with research dedicated to glioblastoma multiforme.If your time is valuable, this book is for you. First, you will not waste time searching the Internet while missing a lot of relevant information. Second, the book also saves you time indexing and defining entries. Finally, you will not waste time and money printing hundreds of...

21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma, Glioblastoma

21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma, Glioblastoma
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about adult brain tumors includes official medical data on signs, symptoms, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of brain cancer - covering gliomas, astrocytomas, meningiomas, oligodendrogliomas, ependymomas, glioblastomas, and many others.

Comprehensive data on clinical trials...

Glioblastoma Multiforme

Glioblastoma Multiforme
by James Markert (Author), Vincent T. DeVita Jr. (Author), Steven A. Rosenberg (Author), Samuel Hellman (Author)


This book provides basic researchers and clinicians with a contemporary review of the epidemiology, diagnosis, and treatment of Glioblastoma Multiforme, the most common and most deadly type of brain tumor. Expert malignant glioma researchers and clinicians provide state-of-the-art chapters on important topics such as molecular genetic classification of glioblastoma, surgical management, stem cell therapy, chemotherapy, angiogenesis, and more.

Glioblastoma, 1e

Glioblastoma, 1e
by Steven Brem MD (Author), Kalil G. Abdullah MD (Author)


Clinically focused and designed to provide a to-the-point overview, Glioblastoma, by Drs. Steven Brem and Kalil G. Abdullah, brings you up to date with increased understanding, new treatment protocols, and recent advances in the field. Written by contributing specialists who are global experts in their respective areas, this one-stop reference provides neurosurgeons, medical-and-radiation oncologists, neuro-oncologists, neuropathologists, internal medicine physicians, and researchers with a dependable source of information on current treatment options, tumor recurrence, and patient care. Evidence for current treatment options for de novo and recurrent glioblastoma, indications for local and topical therapies, immunotherapy, gene therapy, nanotherapy, small-molecule inhibition, electric...

Glioblastoma:: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies

Glioblastoma:: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies
by Swapan K. Ray (Editor)


Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for...

Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About

Surviving "Terminal" Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About
by Ben A. Williams Ph.D. (Author)


An account of dealing with glioblastoma brain cancer, along with the information needed to survive it

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer


“Although, your health condition may impact your everyday life, do not let it define who you are.”

AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg,...

Advances in the treatment of newly diagnosed glioblastoma

Advances in the treatment of newly diagnosed glioblastoma
by Valencia Press (Author)


Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising...

© 2017 BrightSurf.com